Pharma Mar, S.A. (LON:0RC6)

Market Cap	1.41B
Revenue (ttm)	138.97M
Net Income (ttm)	517.59K
Shares Out	n/a
EPS (ttm)	0.03
PE Ratio	2,730.30
Forward PE	n/a
Dividend	0.55 (0.74%)
Ex-Dividend Date	Jun 12, 2024

Volume	1,553
Average Volume	651
Open	74.18
Previous Close	73.87
Day's Range	73.87 - 107.10
52-Week Range	29.46 - 107.10
Beta	-0.00
RSI	70.75
Earnings Date	Feb 28, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 509
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC6

Financial Performance

In 2023, Pharma Mar's revenue was 158.15 million, a decrease of -19.45% compared to the previous year's 196.34 million. Earnings were 1.14 million, a decrease of -97.70%.

Financial numbers in EUR